Health Care • Biotechnology: Pharmaceutical Preparations
$207.83 ▲ +2.77
(+1.35%)
MKT CAP: $13.49B • VOL: 773.7K
52W L $129 52W H $266
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$175
MEDIAN
$233
MEAN
$237
HIGH
$283
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE JAZZ TAPE
JAZZ // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $251.47 | $239.00 | 2025-02-14 | $189.13 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $261.87 | $245.24 | 2025-02-06 | $195.36 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $236.93 | $228.61 | 2025-01-29 | $199.52 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $211.99 | — | 2025-01-17 | $203.67 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $182.89 | $197.44 | 2025-01-09 | $184.97 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $247.32 | $216.14 | 2024-12-18 | $180.81 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $201.60 | $209.91 | 2024-12-04 | $193.28 | -4.3% | 48% | C |